Oditrasertib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Oditrasertib
- Molecular weight
- 295.29
- Structure (SMILES)
- CC(C)(C(=O)N1CCOc2c(C#N)cncc2C1)C(F)F
- c19061501 f
- C19061501-F
- dn 2489
- DN-2489
- dn0002489
- DN0002489
- dn2489
- DN2489
- dnl 788
- DNL-788
- dnl788
- DNL788
- oditrasertib
- Oditrasertib
- oditrasertib [INN]
- ODITRASERTIB [USAN]
- oditrasertib inn
- oditrasertib usan
- ra 15804589
- RA-15804589
- ra15804589
- RA15804589
- sar 443820
- SAR-443820
- sar443820
And 2 more, listed on the interactive page.
- CAS registry numbers
- 2252271-93-3
- ChEMBL ID
- CHEMBL5314474
- InChIKey
- CSCLQCHKUAMZOY-UHFFFAOYSA-N
- PubChem compound IDs
- 135382587
- FDA ingredient codes (UNII)
- I1YQT8HC89
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- oditrasertib
- Type
- Synthetic organic
- Drug name stem
- -sertib
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- receptor interacting serine/threonine kinase 1
- Gene symbol
- RIPK1
- Protein identifier
- Q13546
- Affinity units
- pIC50
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 2
- NCT05237284
- NCT05795907
- NCT05797701
- NCT05797753
- NCT05630547
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 0
- Polar surface area
- 66.22
- Calculated partition coefficient (ALogP)
- 1.97
- Calculated partition coefficient (XLogP)
- 1.3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 21
- Molecular formula
- C14H15F2N3O2
- Monoisotopic mass
- 295.11323305
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (5)
- A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
- A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
- A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
- Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
- Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
In development for (2)
- Amyotrophic lateral sclerosis Phase 2
- Multiple sclerosis Phase 2